A5027442491- Sarcoma Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Neuroblastoma Research and Treatments
- Gastric Cancer Management and Outcomes
- Neurofibromatosis and Schwannoma Cases
- Cancer, Hypoxia, and Metabolism
- Uterine Myomas and Treatments
- Thyroid Cancer Diagnosis and Treatment
- Inflammatory Bowel Disease
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Reproductive Biology and Fertility
- BRCA gene mutations in cancer
- Assisted Reproductive Technology and Twin Pregnancy
- Biosimilars and Bioanalytical Methods
- Cancer Diagnosis and Treatment
- Microscopic Colitis
- Endometrial and Cervical Cancer Treatments
- Vascular Tumors and Angiosarcomas
- Cancer and Skin Lesions
- Histiocytic Disorders and Treatments
- Organ Donation and Transplantation
- Management of metastatic bone disease
- Ear and Head Tumors
University of Bologna
1994-2025
Universitair Ziekenhuis Leuven
2025
VIR Biotechnology (United States)
2024
Azienda USL di Bologna
2021-2023
Policlinico S.Orsola-Malpighi
2017-2022
IRCCS Policlinico San Donato
2007
University of Palermo
2004-2005
Azienda Ospedaliera Ospedale Civile di Legnano
2002
Istituti di Ricovero e Cura a Carattere Scientifico
1993-1995
Istituto Giannina Gaslini
1993-1995
In the era of immunotherapy, identifying biomarkers immune system activation has become a high-priority challenge. The blood neutrophil-to-lymphocyte ratio (NLR) been largely investigated as biomarker in several cancer types. NLR values have shown to mirror tumor-induced inflammatory status and demonstrated be reliable prognostic tool across stages disease therapeutic approaches. When integrated with other response such PD-L1, tumor mutational burden, tumor-associated cells, may allow...
Abstract Background Extending the infliximab (IFX) infusion interval has been attempted in patients with Crohn’s disease (CD) and ulcerative colitis (UC) who maintained response following an earlier shortening. We compared therapeutic drug monitoring (TDM) model-informed precision dosing (MIPD) for successful de-escalation of dosage these patients. Methods MODIFI is a monocentric, open-label, historically controlled Phase 4 trial (NCT04982172). Eligible steroid-free clinical (two-item...
Importance The D842V platelet-derived growth factor receptor α ( PDGFRA ) mutation identifies a molecular subgroup of gastrointestinal stromal tumors (GISTs), primarily resistant to standard tyrosine kinase inhibitors and with an overall more indolent behavior. Although functional imaging 18 F-fluorodeoxyglucose–labeled positron emission tomography ([ F]FDG-PET) plays proven role in GISTs, especially early assessment tumor response, less is known about [ F]FDG uptake according the GIST...
Regorafenib (REG) has now been approved as the standard third-line therapy in metastatic gastrointestinal stromal tumour (GIST) patients at recommended dose and schedule of 160 mg once daily for first 3 weeks each 4-week cycle. However, it a relevant toxicity profile that mainly occurs within cycles therapy, adjustments are often required to reduce frequency or severity adverse events avoid early treatment discontinuation. To date, large amounts data on use REG GIST clinical practice not...
•Regorafenib-personalized schedules are commonly adopted in daily clinical practice.•Regorafenib-personalized correlate with statistically significant improvement of therapeutic outcomes.•A prompt personalization regorafenib could help clinicians avoid early treatment discontinuation due to adverse events.•A patient-tailored approach be applied other metastatic solid tumors treated regorafenib. BackgroundDespite its proven activity as third-line gastrointestinal stromal (GIST), can present a...
•RAI resistance and time to RAI-R development in advanced DTC are significantly correlated with genetic profiling.•Genetic testing allows for identifying the subset of more aggressive those actionable gene fusions.•Genetic should be included as part clinical workup carried out early possible all DTCs. BackgroundTumor genotyping is becoming crucial optimize management patients differentiated thyroid cancer (DTC); however, its implementation practice remains undefined. We herein report our...
In the aftermath of COVID-19 pandemic, opportunities to modulate biological pathways common lifecycles viruses need be carefully considered.
Uterine leiomyosarcoma (uLMS) is a rare and aggressive malignancy with poor clinical outcomes. Even when localized, uLMS associated high rates of local distant recurrences that are usually fatal. Common sites recurrence lung, liver, pelvic lymph nodes, vertebral long bones although atypical patterns have been described. Among them, intracranial appears as finding, almost exceptional in skull dura. Herein, we describe the case solitary metastasis from 39-year-old woman, which represents third...
Background and Objective: Adenosarcoma is a rare subtype of uterine sarcoma, composed by combination benign epithelial malignant, but generally low grade, mesenchymal component it considered the least aggressive form its counterpart, carcinosarcoma. The presence myometrial invasion extent disease outside uterus determines stage disease, while sarcomatous overgrowth represents most important histological prognostic factor, correlating with grade disease. Because extreme rarity UAS, available...
Angiosarcomas (ASs) are rare malignant vascular entities that can affect several regions in our body, including the heart. Cardiac ASs comprise 25-40% of cardiac sarcomas and cause death within months diagnosis. Thus, aim was to identify potential differences and/or similarities between extra-cardiac enhance targeted therapies and, consequently, patients' prognosis. Whole-transcriptome analysis three eleven non-cutaneous samples performed investigate differential gene expression mutational...
Background Positron emission tomography (PET) with 18-fluorodeoxyglucose ( 18 FDG) has proven to be highly sensitive in the early assessment of tumor response gastrointestinal stromal tumors (GIST), especially cases where there is doubt or when prediction could clinically useful for patient management. As widely known, kinase mutations have an undoubtful predictive value sensitivity imatinib, and inclusion KIT PDGFRa mutational analysis diagnostic workup all GIST now considered standard...